New Weight Loss Drugs Coming Out in 2026: What You Can Actually Get

The new weight loss drugs actually available in 2026 are two pills: the Wegovy pill (oral semaglutide 25 mg), approved December 22, 2025, and Foundayo (orforglipron), approved April 1, 2026 ^[4][3]. Everything else making headlines is still investigational: CagriSema is under FDA review and not approved in the US or EU ^[5], survodutide has not been approved for use ^[7], and petrelintide is still in trials ^[6]. Retatrutide goes further — as an investigational molecule, it cannot be legally sold or marketed for human use ^[2].

The pipeline behind those headlines is large. The Ozmosi drug intelligence platform tracks more than 150 active obesity and weight-related programs, from preclinical work through Phase 3 ^[1]. More than 1 billion people worldwide were living with obesity in 2022, including about 890 million adults, and that market has pulled investment into mechanisms well beyond GLP-1s, including amylin receptor agonists, RNAi therapies, muscle-preservation agents and CB1 antagonists ^[1].

How big is the obesity drug pipeline right now?

Beyond the more than 150 active programs Ozmosi tracks, the mechanism list has widened considerably ^[1]. Established incretin pathways (GLP-1, GIP, glucagon) now sit alongside amylin receptor agonists, RNAi therapies targeting INHBE and ALK7, drugs meant to preserve muscle during weight loss, CB1 antagonists, and therapies for rare forms of obesity ^[1].

The 2026 landscape has already shifted in several concrete ways, according to Ozmosi’s August 17, 2026 analysis: Foundayo received FDA approval on April 1; retatrutide produced pivotal Phase 3 obesity results; AstraZeneca advanced elecoglipron into Phase 3; Structure Therapeutics began dosing patients in its Phase 3 aleniglipron program; and Novo Nordisk’s CagriSema went under FDA review ^[1].

What new weight loss drugs are already FDA-approved?

Two oral GLP-1 medicines for weight management are now approved in the United States, which means patients who dislike needles no longer necessarily have to accept substantially less effective treatment ^[1].

The Wegovy pill (once-daily oral semaglutide 25 mg) was approved on December 22, 2025 as the first oral GLP-1 for obesity in the US ^[4]. It is indicated, along with a reduced-calorie diet and increased physical activity, for adults with obesity or overweight with weight-related medical problems, and it is also indicated to reduce the risk of major adverse cardiovascular events such as death, heart attack or stroke in adults with overweight or obesity and established cardiovascular disease ^[4]. It launched in the US in early January 2026, with the 1.5 mg starting dose in pharmacies at that time ^[4].

Foundayo (orforglipron), made by Lilly, was approved April 1, 2026 for adults with obesity, or overweight with weight-related medical problems ^[3]. It is a once-daily small-molecule (non-peptide) oral GLP-1 receptor agonist that can be taken at any time of day without restrictions on food or water ^[3][1]. Prescriptions were accepted through LillyDirect starting April 1, with shipping from April 6 ^[3]. Orforglipron was discovered by Chugai Pharmaceutical and licensed by Lilly in 2018 ^[3].

One point worth understanding: oral semaglutide is peptide-based while Foundayo is a small molecule, but both still act on the GLP-1 receptor. Changing the delivery method does not make either one a different drug class, and neither is free of gastrointestinal side effects ^[1].

The table below shows the headline numbers for approved drugs, using the highest-dose results in adults with obesity or overweight without type 2 diabetes, where comparable data are available ^[1].

Drug	Status	Format	Average weight loss	Trial duration
Wegovy (semaglutide), Novo Nordisk	Approved	GLP-1; weekly injection	16.9%	68 weeks [1]
Zepbound (tirzepatide), Eli Lilly	Approved	GIP + GLP-1; weekly injection	22.5%	72 weeks [1]
Wegovy pill (semaglutide), Novo Nordisk	Approved Dec. 2025	GLP-1; daily pill	16.6%	64 weeks [1][4]
Foundayo (orforglipron), Eli Lilly	Approved Apr. 2026	GLP-1; daily pill	12.4%	72 weeks [1][3]

These figures come from separate trials with different designs, durations and populations, so they cannot be used to rank one drug against another — that would require head-to-head studies ^[1].

How well did the two approved pills work in their trials?

The Wegovy pill’s approval rests on OASIS 4, a 64-week Phase 3 trial of 307 adults with obesity or overweight plus at least one weight-related comorbidity and no diabetes, randomized 2:1 to once-daily oral semaglutide 25 mg or placebo ^[4]. If all patients had stayed on treatment, the Wegovy pill group lost about 17% (16.6%) of body weight versus about 3% (2.7%) for placebo; counting everyone regardless of whether they stayed on treatment, the figures were about 14% (13.6%) versus about 2% (2.4%) ^[4]. In the Wegovy pill group, 76% lost at least 5% of body weight from a baseline of 235 lb, versus 31% of the placebo group ^[4].

Foundayo’s approval rests on the ATTAIN program, which enrolled more than 4,500 people with obesity or overweight across ATTAIN-1 and ATTAIN-2 ^[3]. ATTAIN-1 was a 72-week Phase 3 trial that randomized 3,127 adults with obesity, or overweight with at least one comorbidity such as hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, and without diabetes ^[3]. Those on the highest dose who stayed on treatment lost an average of 27.3 lb (12.4%) versus 2.2 lb (0.9%) with placebo; counting all participants regardless of completion, the averages were 25 lb (11.1%) versus 5.3 lb (2.1%) ^[3].

What do the new pills cost?

Manufacturer self-pay and savings figures are not list prices, and they are not a guaranteed out-of-pocket cost — these programs are conditional and can change ^[1]. With that caveat, here is what the manufacturers have announced:

Option	Announced patient cost	Conditions
Foundayo, commercial insurance	As little as $25/month	With the Foundayo savings card [3]
Foundayo, self-pay	From $149/month	Lowest dose [3][1]
Foundayo, Medicare Part D	$50/month	Eligible patients may be able to get it, beginning as soon as July 1, 2026 [3]
Wegovy pill 1.5 mg starting dose	$149/month	With savings offers [4]
Oral Wegovy, self-pay	From $149/month	Novo Nordisk self-pay pricing [1]
Zepbound, self-pay	From $299/month	Lilly self-pay pricing [1]

On the insurance side, since July 2026 eligible Medicare Part D beneficiaries have been able to obtain certain approved GLP-1 obesity medicines for $50 per month through the temporary Medicare GLP-1 Bridge program ^[1].

What is CagriSema and when might the FDA decide?

CagriSema is the candidate closest to an FDA decision. Novo Nordisk submitted a New Drug Application on December 18, 2025 for once-weekly CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) for chronic weight management in adults with obesity or overweight plus at least one weight-related comorbid condition ^[5]. If approved, it would be the first injectable combination of a GLP-1 receptor agonist and an amylin analog ^[5].

The FDA is expected to review the application in 2026, and it remained under review as of Ozmosi’s August 17, 2026 analysis ^[5][1]. CagriSema is not approved in the US or the EU ^[5].

The application is based on REDEFINE 1, a 68-week Phase 3 trial in 3,417 adults with obesity or overweight plus at least one obesity-related complication and no diabetes, comparing CagriSema with semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, and placebo ^[5]. Using the trial-product estimand (the effect if all patients stayed on treatment), the CagriSema group lost an average of 22.7% of body weight at 68 weeks versus 2.3% for placebo; using the treatment-policy estimand (everyone counted regardless of staying on treatment), the figures were 20.4% from a baseline of 236 lb versus 3.0% ^[5]. Some 91.9% of CagriSema participants lost at least 5% of body weight versus 31.5% on placebo, and 54% of those with obesity at baseline dropped below a BMI of 30 by week 68, versus 11.1% on placebo ^[5].

Tolerability is a real consideration. In REDEFINE 1, 79.6% of the CagriSema group had gastrointestinal adverse events versus 39.9% on placebo, including nausea (55% vs 12.6%), constipation (30.7% vs 11.6%) and vomiting (26.1% vs 4.1%) ^[5]. Discontinuations due to adverse events were 5.9% versus 3.5% in REDEFINE 1, and 8.4% versus 3% in REDEFINE 2, the companion 68-week trial in 1,206 adults with type 2 diabetes and obesity or overweight ^[5]. Ongoing trials include REDEFINE 3, a cardiovascular outcomes trial, and REDEFINE 11, a longer-duration trial in patients with BMI of 30 or more ^[5].

What is retatrutide and when will it be available?

Retatrutide is Eli Lilly’s investigational once-weekly injection — a single molecule that activates receptors for GIP, GLP-1 and glucagon ^[2]. It has generated enormous interest because it targets three hormone receptors rather than one or two ^[1]. In the Phase 3 TRIUMPH-1 trial, participants on the highest dose lost an average of 28.3% of body weight at 80 weeks, and among extension participants with a starting BMI of at least 35 who continued treatment, average loss reached 30.3% at 104 weeks ^[1].

On July 23, 2026, Lilly announced positive topline results from two more Phase 3 trials ^[2]. In TRIUMPH-2, which randomized 1,152 adults with type 2 diabetes and obesity or overweight, the 4 mg, 9 mg and 12 mg groups lost an average of 12.7% (29.8 lb), 19.1% (45.4 lb) and 20.8% (49.6 lb) at 80 weeks respectively, versus 4.0% on placebo, with A1C reductions of up to 1.6% ^[2]. In TRIUMPH-3, which randomized 1,949 adults with severe obesity (BMI 35 or above) and established cardiovascular disease, participants lost 21.6% at 9 mg and 22.6% (55.8 lb) at 12 mg versus 3.2% on placebo ^[2].

The timeline is the catch. Lilly says it plans to submit a Biologics License Application to the FDA in Q1 2027 ^[2][1]. Retatrutide is investigational, cannot be legally sold or marketed for human use, and is not available by prescription ^[2][1]. It is also still a once-weekly injection with GLP-1 activity as part of its mechanism, and it is being studied in Phase 3 for knee osteoarthritis pain, obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and MASLD ^[2][1].

Side effects resemble the class. In TRIUMPH-2 at the 12 mg dose versus placebo: diarrhea 33.6% vs 13.2%, nausea 28.0% vs 8.0%, vomiting 15.7% vs 4.2% ^[2]. Discontinuations due to adverse events were 3.8% (4 mg), 11.6% (9 mg) and 7.7% (12 mg) versus 4.9% placebo in TRIUMPH-2, and 9.8% (9 mg) and 13.5% (12 mg) versus 4.8% placebo in TRIUMPH-3 ^[2]. On cardiovascular events, TRIUMPH-3 recorded 44 MACE-5 events in the pooled retatrutide groups versus 52 on placebo (hazard ratio 0.82, 95% CI 0.55–1.22), and 27 MACE-3 events versus 23 (hazard ratio 1.12, 95% CI 0.64–1.96) ^[2].

What is survodutide?

Survodutide (BI 456906) is Boehringer Ingelheim’s investigational glucagon/GLP-1 receptor dual agonist; it has not been approved for use, and its efficacy and safety have not been established ^[7]. On April 28, 2026 the company announced topline results from SYNCHRONIZE-1, a Phase 3 trial that met its co-primary endpoints on both the efficacy and treatment-regimen estimands ^[7]. Adults with obesity or overweight without type 2 diabetes lost up to an average of 16.6% of body weight at 76 weeks versus 3.2% on placebo (p<0.0001), or up to 39.2 lb (17.8 kg) ^[7]. Up to 85.1% achieved at least 5% weight reduction versus 38.8% on placebo ^[7].

Initial analysis indicates the weight loss was driven predominantly by fat tissue, with lean mass contributing only a small proportion, and the waist-circumference secondary endpoint was met ^[7]. Gastrointestinal events were as expected for the GLP-1 class, with discontinuations more frequent during dose escalation; these events were described as mild to moderate and temporary ^[7]. Full data were slated for presentation at the ADA Scientific Sessions in June 2026 ^[7]. Survodutide is also in Phase 3 LIVERAGE and LIVERAGE-Cirrhosis trials for MASH, and has held FDA Fast Track (May 2021) and Breakthrough Therapy (September 2024) designations for MASH ^[7]. Boehringer’s BI 3034701, a triple GLP-1/GIP/NPY2 receptor agonist peptide, is entering Phase 2 in mid-2026 ^[7].

Are there weight loss drugs that are not GLP-1s?

Yes, but none is approved yet. The most advanced non-GLP-1 candidate is petrelintide, a long-acting amylin analog from Zealand Pharma and Roche given as a once-weekly injection that does not rely on GLP-1 receptor agonism ^[6][1]. According to Zealand Pharma, amylin is produced in the pancreatic beta cells and co-secreted with insulin in response to nutrients, and the company says amylin receptor activation has been shown — in research it cites — to reduce body weight by restoring sensitivity to the satiety hormone leptin and inducing a feeling of fullness faster ^[6].

In the Phase 2 ZUPREME-1 trial, petrelintide produced up to 10.7% average weight loss at 42 weeks ^[1]. At the maximally effective dose, Roche reported no vomiting and no discontinuations caused by gastrointestinal adverse events, with overall tolerability similar to placebo ^[1]. Those are unusually encouraging tolerability results, but petrelintide must still confirm its efficacy and tolerability in Phase 3 before it can become a treatment option ^[1]. Phase 3 chronic weight management trials were endorsed on April 29, 2026, with initiation planned for the second half of 2026, and a Phase 2 trial of petrelintide combined with Roche’s GLP-1/GIP dual agonist enicepatide (CT-388) is planned to start in the second quarter of 2026 ^[6].

Cagrilintide, the amylin analog in CagriSema, is another example of this mechanism reaching late-stage development, though in combination with a GLP-1 drug ^[5]. Further back, RNAi therapies targeting INHBE or ALK7, CB1-targeted drugs and muscle/fat signaling therapies are all further from approval than the incretins ^[1].

What other oral GLP-1 pills are in development?

Several more oral GLP-1 candidates could expand pill options if their late-stage programs succeed ^[1]. AstraZeneca’s elecoglipron advanced into Phase 3 during 2026, and Structure Therapeutics has begun dosing patients in its Phase 3 aleniglipron program ^[1]. Oral zenagamtide is also named among the additional oral candidates that could widen choice ^[1].

Is any pipeline drug designed to protect muscle while losing fat?

Some are being designed with body composition in mind, but none is close to pharmacies. Wave Life Sciences’ WVE-007, an RNAi therapy targeting INHBE, produced a placebo-adjusted 14.3% reduction in visceral fat at six months after a single Phase 1 dose, with lean mass maintained — though total body-weight reduction was modest ^[1]. WVE-007 is very early in development, and those results should not be read as evidence that a muscle-preserving obesity drug is about to reach pharmacies ^[1]. Myostatin and activin inhibitors are also being studied for their effects on muscle and body composition ^[1].

How do I compare weight-loss percentages without being misled?

Two things trip people up: which estimand is being used, and how long the trial ran.

An efficacy or trial-product estimand estimates the effect if every randomized participant had stayed on treatment and used no other weight-loss therapy; a treatment-policy or treatment-regimen estimand counts everyone regardless of whether they stayed on treatment ^[5][4][2]. The gap can be sizable. Foundayo: 12.4% for those who stayed on treatment versus 11.1% for all participants ^[3]. CagriSema: 22.7% versus 20.4% ^[5]. Wegovy pill: about 17% versus about 14% ^[4].

Trial durations also differ widely across the programs cited here — 42, 64, 68, 72, 76, 80 and 104 weeks — which makes side-by-side percentages even harder to compare ^{[1][2][3][4][5][7]}. Ozmosi’s own comparison table is deliberately restricted to highest-dose results in adults with obesity or overweight without type 2 diabetes, where comparable data are available, and even then the numbers come from separate trials rather than head-to-head studies ^[1].

What side effects and warnings come with the new drugs?

The approved pills carry the same class warnings as the injections. Foundayo’s labeling states it may cause thyroid tumors, including thyroid cancer, and that it should not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 ^[3]. Its listed serious risks include pancreatitis, severe stomach problems, dehydration leading to kidney problems, low blood sugar when combined with insulin or sulfonylureas, serious allergic reactions, vision changes in people with type 2 diabetes, and gallbladder problems ^[3]. Its most common side effects are nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, bloating, fatigue, belching, heartburn, gas and hair loss ^[3]. Foundayo should not be used with other GLP-1 receptor agonist medicines, and its safety in children is unknown ^[3].

Wegovy carries warnings about possible thyroid tumors including medullary thyroid carcinoma, pancreatitis, gallbladder problems and low blood sugar; the label also says to stop Wegovy two months before a planned pregnancy and that breastfeeding is not recommended while taking Wegovy tablets ^[4]. In OASIS 4, common adverse reactions were similar to those seen with Wegovy injection 2.4 mg — nausea, diarrhea and vomiting ^[4].

Whether a particular medicine is appropriate is a decision for a clinician who knows a person’s full medical history.

What actually changes for patients in 2026?

The practical change is choice. Two oral GLP-1 options for weight management are now FDA-approved in the US, so patients who dislike needles no longer necessarily have to accept substantially less effective treatment ^[1]. But switching among incretin-based drugs, oral or injectable, does not eliminate the risk of nausea or vomiting — Foundayo still commonly causes gastrointestinal side effects ^[1].

Retatrutide, despite its 28.3% headline number, remains investigational and not prescribable, with a BLA planned for Q1 2027 ^[1][2]. When Lilly announced Foundayo’s approval, its CEO David Ricks said fewer than 1 in 10 people who could benefit from a GLP-1 are taking one ^[3]. Wegovy has been prescribed to approximately 3.2 million people in the US ^[4].

Finally, not all experimental therapies will succeed, and whether competition actually lowers prices depends on insurance coverage, manufacturer pricing and public policy ^[1]. The pipeline is a reason for optimism about choice — not a guarantee about cost.

Sources

1. Ozmosi. The obesity drug pipeline in 2026: emerging targets, companies and clinical readouts. August 17, 2026.
2. Eli Lilly and Company. Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. July 23, 2026.
3. Eli Lilly and Company. FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. April 1, 2026.
4. PR Newswire. FDA approves Novo Nordisk’s Wegovy pill, the first and only oral GLP-1 for weight loss in adults.
5. PR Newswire. Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management.
6. GlobeNewswire. Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management. April 29, 2026.
7. Boehringer Ingelheim. Survodutide achieved significant weight loss in Phase III SYNCHRONIZE-1 obesity trial. April 28, 2026.
8. Pfizer. Robust Phase 2b efficacy and favorable tolerability support monthly dosing for Pfizer’s GLP-1 RA berobenatide. June 6, 2026.
9. BioSpace. Correction: Amgen. May 1, 2026.
10. AstraZeneca. Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio. June 8, 2026.
11. BioSpace. Structure Therapeutics reports positive clinical data across oral small molecule amylin and GLP-1 programs for chronic weight management. September 8, 2026.
12. Viking Therapeutics. Viking Therapeutics reports second quarter 2026 financial results and provides corporate update. July 29, 2026.
13. Fierce Biotech. Roche sees GLP1/GIP drug from Carmot produce 22.5% weight loss, readies phase 3 trial. January 27, 2026.
14. PR Newswire. Mazdutide 9 mg achieves up to 20.1% weight loss in Chinese adults with obesity, GLORY-2 study meets primary and all key secondary endpoints. November 19, 2025.
15. PR Newswire. Sciwind Biosciences announces ecnoglutide injection approved by China’s National Medical Products Administration (NMPA) for chronic weight management. March 6, 2026.
16. Rhythm Pharmaceuticals. Rhythm Pharmaceuticals announces FDA approval of IMCIVREE (setmelanotide) for patients with acquired hypothalamic obesity. March 19, 2026.
17. Medscape. Myostatin blocker preserves muscle with GLP-1 treatment. October 6, 2025.
18. Pfizer. Pfizer provides update on oral GLP-1 receptor agonist danuglipron. April 14, 2025.
19. Reuters. Terns Pharma shelves obesity drug after mid-stage trial disappoints. October 21, 2025.
20. GlobeNewswire. Hengrui Pharma and Kailera Therapeutics announce additional data from Phase 3 obesity trial in China of dual GLP-1/GIP receptor agonist HRS9531. November 4, 2025.
21. HCPLive. CagriSema demonstrates weight loss, fails to achieve primary endpoint compared to tirzepatide. February 23, 2026.
22. MPR. REDEFINE 4: CagriSema weight loss results compared with tirzepatide.
23. Reuters. Scholar Rock gets first FDA nod for rare muscle-wasting disease. September 11, 2026.
24. Scholar Rock. Scholar Rock announces FDA approval of ISEMBYLD (apitegromab-mstn), the first and only muscle-targeted treatment for children and adults with spinal muscular atrophy (SMA).